Enobosarm

The FDA has cleared Allogene Therapeutics' IND application for ALLO-329, a dual-targeting allogeneic CAR T-cell therapy, to treat autoimmune diseases.

Phase 2b QUALITY trial demonstrates that Veru's enobosarm significantly reduces lean muscle mass loss in older adults taking GLP-1 agonists for weight loss. Despite achieving its primary objective of muscle preservation, Veru's shares dropped nearly 48% as fat mass reduction data failed to reach statistical significance compared to Wegovy alone.

Helicore Biopharma, backed by Versant Ventures and OrbiMed, launches with $65 million in Series A funding to develop GIP-targeting therapies for obesity.

Phase IIb QUALITY trial demonstrates significant improvements in lean mass retention and fat loss when combining enobosarm with semaglutide, compared to placebo.

The FDA has granted approval for monthly maintenance dosing of Leqembi (developed by Eisai and Biogen) for early Alzheimer's disease patients. After 18 months of bi-weekly treatment, patients can transition to monthly dosing at half the original dose, based on Phase 2 study results and modeling simulations demonstrating sustained therapeutic benefits.